Trastuzumab Recruiting Phase 2 Trials for Invasive Ductal Breast Carcinoma / Inflammatory carcinoma of the breast / HER2 Positive Breast Cancers / Tubular Breast Cancer Stage III / Tubular Breast Cancer Stage II / Malignant Neoplasm of Female Breast / Mucinous Breast Cancer Stage II Treatment

Indications	Status	Purpose	Phase
DBCOND0047004 (Invasive Ductal Breast Carcinoma) DBCOND0017409 (Inflammatory carcinoma of the breast) DBCOND0066412 (HER2 Positive Breast Cancers) DBCOND0053764 (Tubular Breast Cancer Stage III) DBCOND0053760 (Tubular Breast Cancer Stage II) DBCOND0064161 (Malignant Neoplasm of Female Breast) DBCOND0053761 (Mucinous Breast Cancer Stage II)	Recruiting	Treatment	2

clinicaltrials.gov Identifier	Title	Drugs
NCT02614794	A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer	Tucatinib (DB11652) Capecitabine (DB01101) Trastuzumab (DB00072)
NCT02682693	Denosumab as an add-on Neoadjuvant Treatment (GeparX)	Pertuzumab (DB06366) Denosumab (DB06643) Cyclophosphamide (DB00531) Paclitaxel (DB01229) Epirubicin (DB00445) Trastuzumab (DB00072) Carboplatin (DB00958)